Fontoura P

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (2)

Title : Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease - Bateman_2022_Alzheimers.Res.Ther_14_178
Author(s) : Bateman RJ , Cummings J , Schobel S , Salloway S , Vellas B , Boada M , Black SE , Blennow K , Fontoura P , Klein G , Assuncao SS , Smith J , Doody RS
Ref : Alzheimers Res Ther , 14 :178 , 2022
Abstract : Bateman_2022_Alzheimers.Res.Ther_14_178
ESTHER : Bateman_2022_Alzheimers.Res.Ther_14_178
PubMedSearch : Bateman_2022_Alzheimers.Res.Ther_14_178
PubMedID: 36447240

Title : Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD) - Nave_2017_J.Alzheimers.Dis_58_1217
Author(s) : Nave S , Doody RS , Boada M , Grimmer T , Savola JM , Delmar P , Pauly-Evers M , Nikolcheva T , Czech C , Borroni E , Ricci B , Dukart J , Mannino M , Carey T , Moran E , Gilaberte I , Muelhardt NM , Gerlach I , Santarelli L , Ostrowitzki S , Fontoura P
Ref : J Alzheimers Dis , 58 :1217 , 2017
Abstract : Nave_2017_J.Alzheimers.Dis_58_1217
ESTHER : Nave_2017_J.Alzheimers.Dis_58_1217
PubMedSearch : Nave_2017_J.Alzheimers.Dis_58_1217
PubMedID: 28550255